Malignant Retroperitoneal Neoplasm — Trials

Malignant Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 41
Recruiting: 23
Ph III recruiting: 1
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (17)

clinicaltrialsPublishedShowing 1–21 of 21 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06900595	Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer	recruiting	Phase 2	48	National Cancer Institute (NCI)NIH	1	Sep 18, 2026	clinicaltrials
NCT07743138	STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)	not yet recruiting	Phase 2	20	M.D. Anderson Cancer CenterOTHER